Perkembangan Terapi Sistemik pada Pruritus

Melody Febriana Andardewi; Windy Keumala Budianti; Lili Legiawati; Yudo Irawan

doi:10.36452/jkdoktmeditek.v28i1.2203

Authors

Melody Febriana Andardewi Departemen Dermatologi dan Venereologi Fakultas Kedokteran Universitas Indonesia RSUPN dr. Cipto Mangunkusumo Jakarta, Indonesia
Windy Keumala Budianti Departemen Dermatologi dan Venereologi Fakultas Kedokteran Universitas Indonesia RSUPN dr. Cipto Mangunkusumo Jakarta, Indonesia
Lili Legiawati Departemen Dermatologi dan Venereologi Fakultas Kedokteran Universitas Indonesia RSUPN dr. Cipto Mangunkusumo Jakarta, Indonesia
Yudo Irawan Departemen Dermatologi dan Venereologi Fakultas Kedokteran Universitas Indonesia RSUPN dr. Cipto Mangunkusumo Jakarta, Indonesia

DOI:

https://doi.org/10.36452/jkdoktmeditek.v28i1.2203

Keywords:

panduan terapi, pruritus, terapi terkini

Abstract

Pruritus merupakan sensasi tidak nyaman yang mencetuskan keinginan untuk menggaruk. Sensasi tersebut disebabkan oleh berbagai hal, misalnya penyakit kulit, penyakit sistemik, atau idiopatik, gangguan psikiatri, serta penyakit neurologis. Pruritus menjadi masalah kesehatan karena dapat memberi dampak negatif terhadap kualitas hidup pasien. Pendekatan tata laksana pruritus diberikan secara bertingkat mulai dari terapi dasar, terapi target, dan terapi simtomatik. Pada kasus pruritus kronik yang refrakter maupun pruritus tanpa sebab yang diketahui, terapi simtomatik berperan besar dan dapat diberikan pada pasien tersebut. Tata laksana pada pruritus kronik saat ini banyak diteliti seiring dengan ditemukan berbagai mekanisme yang mendasari terjadinya pruritus. Sesuai dengan patofisiologi dari pruritus, terapi sistemik yang dikembangkan menargetkan pada reseptor spesifik di sistem saraf dan sistem imunitas yang berperan pada jalur sinyal pruritus. Berbagai terapi terbaru yang masih diteliti dalam uji klinis menunjukkan hasil yang menjanjikan dan berpotensi menjadi pilihan terapi pada pasien dengan pruritus kronik.

References

Stander S. Classification of itch. Curr Probl Dermatol. 2016;50:1-4.

Stander S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, dkk. Clinical classification of itch: A position paper of the international forum for the study of itch. Acta Derm Venereol. 2007;87(4):291-4.

Mollanazar NK, Koch SD, Yosipovitch G. Epidemiology of chronic pruritus: Where have we been and where are we going? Curr Derm Rep. 2015;4(1):20-9.

Golpanian RS, Yosipovitch G. Current and emerging systemic treatments targeting the neural system for chronic pruritus. Expert Opin Pharmacother. 2020;21(13):1629-36.

Yosipovitch G, Rosen JD, Hashimoto T. Itch: From mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018;142(5):1375-90.

Mollanazar NK, Smith PK, Yosipovitch G. Mediators of chronic pruritus in atopic dermatitis: Getting the itch out? Clin Rev Allergy Immunol. 2016;51(3):263-92.

Stander S, Pereira MP, Luger TA. Neurobiology of the skin. Dalam: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, Orringer, penyunting. Fitzpatrick’s dermatology. Edisi ke-9. New York: McGraw-Hill; 2019. h. 351-61.

Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J. Pruritus: Progress toward pathogenesis and treatment. Biomed Res Int. 2018:1-12.

Stander S, Luger TA. Nk-1 antagonists and itch. Handb Exp Pharmacol. 2015;226:237-55.

Fowler E, Yosipovitch G. A new generation of treatments for itch. Acta Derm Venereol. 2020 7;100(2):adv00027.

Weisshaar E, Szepietowski JC, Dalgard FJ, Garcovich S, Gieler U, Gimenez-Arnau AM, dkk. European s2k guideline on chronic pruritus. Acta Derm Venereol. 2019;99(5):469-506.

Nowak DA, Yeung J. Diagnosis and treatment of pruritus. Can Fam Physician. 2017;63(12):918-24.

Phinyo P, Koompawichit P, Nochaiwong S, Tovanabutra N, Chiewchanvit S, Chuamanochan M. Comparative efficacy and acceptability of licensed dose second-generation antihistamines in chronic spontaneous urticaria: A network meta-analysis. J Allergy Clin Immunol Pract. 2021;9(2):956-70 e57.

Erickson S, Heul AV, Kim BS. New and emerging treatments for inflammatory itch. Ann Allergy Asthma Immunol. 2021;126(1):13-20.

Thomas J, Saple DG, Jerajani HR, Netha NRG, Rangasamy DU, Shaikh R, dkk. Real-world, non-interventional, observational study of hydroxyzine hydrochloride in chronic pruritus: A prospective, non-comparative study. Dermatol Ther (Heidelb). 2019;9(2):299-308.

Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf. 2020;19(4):467-77.

Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med. 2021;8:638325.

Stull C, Grossman S, Yosipovitch G. Current and emerging therapies for itch management in psoriasis. Am J Clin Dermatol. 2016;17(6):617-24.

Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019;80(3):756-64.

Klejtman T, Beylot-Barry M, Joly P, Richard MA, Debarbieux S, Misery L, dkk. Treatment of prurigo with methotrexate: A multicentre retrospective study of 39 cases. J Eur Acad Dermatol Venereol. 2018;32(3):437-40.

Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochwerg B, dkk. Systemic immunomodulatory treatments for patients with atopic dermatitis: A systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659-67.

Therene C, Brenaut E, Barnetche T, Misery L. Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-analysis. J Invest Dermatol. 2018;138(1):38-45.

Pavlis J, Yosipovitch G. Management of itch in atopic dermatitis. Am J Clin Dermatol. 2018;19(3):319-32.

Maley A, Swerlick RA. Azathioprine treatment of intractable pruritus: A retrospective review. J Am Acad Dermatol. 2015;73(3):439-43.

Sobell JM, Foley P, Toth D, Mrowietz U, Girolomoni G, Goncalves J, dkk. Effects of apremilast on pruritus and skin discomfort/pain correlate with improvements in quality of life in patients with moderate to severe plaque psoriasis. Acta Derm Venereol. 2016;96(4):514-20.

Zebda R, Paller AS. Phosphodiesterase 4 inhibitors. J Am Acad Dermatol. 2018;78(3 Suppl 1):S43-52.

Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, dkk. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies solo 1 and solo 2, ad adol, and chronos. J Am Acad Dermatol. 2020;82(6):1328-36.

Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, dkk. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411-20.

Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, dkk. Tralokinumab for moderate-to-severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase iii trials (ecztra 1 and ecztra 2). Br J Dermatol. 2020;184(3):437-49.

Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab JPSG. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141-50.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, dkk. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-38.

Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, dkk. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (uncover-2 and uncover-3): Results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-51.

Erickson S, Nahmias Z, Rosman IS, Kim BS. Immunomodulating agents as antipruritics. Dermatol Clin. 2018;36(3):1-10.

Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, dkk. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: A randomized clinical trial. JAMA Dermatol. 2020;156(8):863-73.

Feldman SR, Thaci D, Gooderham M, Augustin M, de la Cruz C, Mallbris L, dkk. Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase iii trials in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(6):1162-70 e3.

Pojawa-Golab M, Jaworecka K, Reich A. Nk-1 receptor antagonists and pruritus: Review of current literature. Dermatol Ther (Heidelb). 2019;9(3):391-405.

Alam M, Buddenkotte J, Ahmad F, Steinhoff M. Neurokinin 1 receptor antagonists for pruritus. Drugs. 2021;81:621–34.

Pariser DM, Bagel J, Lebwohl M, Yosipovitch G, Chien E, Spellman MC. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. J Am Acad Dermatol. 2020;82(6):1314-20.

Andrade A, Kuah CY, Martin-Lopez JE, Chua S, Shpadaruk V, Sanclemente G, dkk. Interventions for chronic pruritus of unknown origin. Cochrane Database Syst Rev. 2020;1:CD013128.

Ekelem C, Juhasz M, Khera P, Mesinkovska NA. Utility of naltrexone treatment for chronic inflammatory dermatologic conditions: A systematic review. JAMA Dermatol. 2019;155(2):229-36.

Jaiswal D, Uzans D, Hayden J, Kiberd BA, Tennankore KK. Targeting the opioid pathway for uremic pruritus: A systematic review and meta-analysis. Can J Kidney Health Dis. 2016;3:1-9.

Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020;12:1-172.

Malekmakan L, Tadayon T, Pakfetrat M, Mansourian A, Zareei N. Treatments of uremic pruritus: A systematic review. Dermatol Ther. 2018;31(5):e12683.

Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, dkk. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial. Hepatol Res. 2017;47(10):972-82.

Golpanian RS, Yosipovitch G, Levy C. Use of butorphanol as treatment for cholestatic itch. Dig Dis Sci. 2020:1-7.

Mathur VS, Kumar J, Crawford PW, Hait H, Sciascia T, Investigators TRS. A multicenter, randomized, double-blind, placebo-controlled trial of nalbuphine er tablets for uremic pruritus. Am J Nephrol. 2017;46(6):450-8.

Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: A prospective, randomized, double-blind study. Int Urol Nephrol. 2015;47(1):161-7.

Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: A randomized single blind clinical trial. Hemodial Int. 2017;21(1):63-71.

Kouwenhoven TA, van de Kerkhof PCM, Kamsteeg M. Use of oral antidepressants in patients with chronic pruritus: A systematic review. J Am Acad Dermatol. 2017;77(6):1068-73 e7.

Pakfetrat M, Malekmakan L, Hashemi N, Tadayon T. Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from southern iran. Hemodial Int. 2018;22(1):103-9.

Zhong CS, Elmariah SB. Phototherapy for itch. Dermatol Clin. 2020;38(1):145-55.

Legat FJ. The antipruritic effect of phototherapy. Front Med. 2018;5:333.

Pereira MP, Stander S. Therapy for pruritus in the elderly: A review of treatment developments. Expert Opin Pharmacother. 2018;19(5):443-50.

Patel SP, Vasavda C, Ho B, Meixiong J, Dong X, Kwatra SG. Cholestatic pruritus: Emerging mechanisms and therapeutics. J Am Acad Dermatol. 2019;81(6):1371-8.

Cao T, Tey HL, Yosipovitch G. Chronic pruritus in the geriatric population. Dermatol Clin. 2018;36(3):199-211.

Chung BY, Um JY, Kim JC, Kang SY, Park CW, Kim HO. Pathophysiology and treatment of pruritus in elderly. Int J Mol Sci. 2020;22(1):1-12.

Fourzali KM, Yosipovitch G. Management of itch in the elderly: A review. Dermatol Ther (Heidelb). 2019;9(4):639-53.

Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: A systematic review. J Cutan Med Surg. 2020;24(2):174-186.